V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230001321 | 230001401 | 1.64 | null | Curative (C) | 2018-02-11 | 2018-02-17 | CARBOPLATIN + PACLITAXEL | 02 | N | 230011074 | RITUXIMAB |
| 230001322 | 230001401 | 1.8 | 126.8 | Palliative (P) | 2016-12-21 | 2017-02-17 | Fluorouricil + Folonic Acid (MdG) | 02 | N | 230011074 | OXALIPLATIN + MDG |
| 230001323 | 230001401 | 1.62 | 73.3 | Adjuvant (A) | 2017-06-20 | 2017-06-20 | Trastuzumab Subcutaneous | 02 | N | 230011074 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 230001324 | 230000930 | 1.73 | 128 | Disease modification (D) | 2014-06-02 | 2014-06-14 | Folfirinox | 2 | N | 230011482 | SORAFENIB |
| 230001325 | 230001743 | 1.63 | null | Curative (C) | 2018-08-06 | 2018-08-25 | Trastuzumab 21 day maintenance | N | null | 230011556 | CAPECITABINE + OXALIPLATIN |
| 230001326 | 230000932 | 1.8 | 67.2 | Palliative (P) | 2016-11-04 | 2017-02-23 | Doxorubicin + Ifosfamide | N | N | 230011592 | FEC |
| 230001327 | 230000933 | 1.56 | 95.4 | Adjuvant (A) | 2018-12-11 | 2018-12-11 | Oxaliplatin + Modified de Gramont | 02 | N | 230011728 | FCR |
| 230001328 | 230000934 | 1.84 | 83.3 | Adjuvant (A) | 2016-06-08 | 2016-06-29 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | 230011728 | PAZOPANIB |
| 230001329 | 230000935 | 1.72 | 51.7 | Palliative (P) | 2017-10-13 | 2017-10-14 | Capecitabine + Oxaliplatin 21day | 02 | N | 230011799 | TRASTUZUMAB |
| 230001330 | 230000936 | null | 51.8 | Palliative (P) | 2017-03-02 | 2017-03-02 | Irinotecan + Modified De Gramont | N | N | 230011851 | CAPECITABINE + OXALIPLATIN |
| 230001331 | 230000937 | 1.54 | 57.75 | Palliative (P) | 2017-05-03 | 2017-05-17 | Trial Unspecified | 02 | N | 230012015 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 230001332 | 230001608 | 1.6 | null | Palliative (P) | null | 2016-10-06 | AFLIBERCEPT + FU + IRINOTECAN | N | N | 230012070 | IRINOTECAN |
| 230001333 | 230000939 | 1.7 | 97.6 | null | null | 2018-02-17 | Rituximab (Maintenance) | N | N | 230012155 | CISPLATIN + ETOPOSIDE |
| 230001334 | 230000941 | 1.64 | 62.2 | Not known (9) | 2018-04-13 | 2018-04-13 | CETUXIMAB + MDG | N | N | 230012213 | IRINOTECAN + MDG |
| 230001335 | 230000942 | 1.8 | 60.7 | Palliative (P) | 2017-07-28 | 2017-07-29 | Capecitabine + Oxaliplatin 21day | null | null | 230012315 | CVP R |
| 230001336 | 230000943 | 1.75 | 69.5 | Palliative (P) | 2019-06-30 | 2019-07-07 | IGEV R | N | N | 230012388 | RITUXIMAB |
| 230001337 | 230000944 | 1.7 | null | Not known (9) | 2017-02-09 | 2017-02-13 | Fluorouricil + Folonic Acid (MdG) | N | N | 230012985 | CARBOPLATIN |
| 230001338 | 230000944 | 1.73 | 73 | Disease modification (D) | 2018-05-31 | 2018-06-08 | Oxaliplatin + Modified de Gramont | N | null | 230012985 | DOCETAXEL + TRASTUZUMAB |
| 230001339 | 230000945 | 1.77 | 82.8 | Adjuvant (A) | 2016-07-07 | 2016-07-20 | Irinotecan + Modified De Gramont | N | N | 230013190 | TRASTUZUMAB |
| 230001340 | 230000946 | 1.7 | 70.5 | Palliative (P) | 2016-09-26 | 2016-10-04 | MPT | N | N | 230013331 | IGEV R |
| 230001341 | 230001407 | 1.74 | 69.6 | Adjuvant (A) | 2018-09-16 | 2018-09-25 | CAPECITABINE + OXALIPLATIN | N | N | 230013331 | FLUOROURACIL |
| 230001342 | 230000947 | 1.81 | 0 | Adjuvant (A) | 2015-10-16 | 2015-11-14 | Capecitabine + Oxaliplatin 21day | N | N | 230013481 | CAPECITABINE |
| 230001343 | 230000949 | 1.84 | 72 | Palliative (P) | 2016-10-29 | 2016-10-29 | BCG Intravesical | 02 | Y | 230013486 | IVE |
| 230001344 | 230000950 | 1.53 | 68.7 | Adjuvant (A) | 2013-11-21 | 2015-12-19 | Oxaliplatin + Modified de Gramont | N | null | 230013531 | OXALIPLATIN + MDG |
| 230001345 | 230000951 | 1.74 | 93.9 | Not known (9) | 2015-08-14 | 2015-09-01 | Irinotecan + Modified De Gramont | N | N | 230013550 | IRINOTECAN + MDG |
| 230001346 | 230000952 | 1.69 | null | Palliative (P) | null | 2018-08-07 | Oxaliplatin + Modified de Gramont | null | N | 230013554 | FEC |
| 230001347 | 230000953 | 1.6 | null | Palliative (P) | 2017-09-07 | 2018-03-20 | BCG Intravesical | null | N | 230013591 | R-EPOCH |
| 230001348 | 230000953 | 1.73 | 61.6 | Palliative (P) | 2018-09-02 | 2018-09-04 | LENVATINIB | 02 | N | 230013591 | FEC |
| 230001349 | 230000954 | 0 | 46.7 | Curative (C) | 2017-02-16 | 2017-02-17 | Trastuzumab Subcutaneous | N | null | 230013808 | TRABECTEDIN |
| 230001350 | 230000955 | 1.76 | null | Adjuvant (A) | 2017-01-14 | 2017-01-16 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 230013831 | RITUXIMAB |
| 230001351 | 230000957 | 1.54 | 92.8 | Curative (C) | 2018-12-27 | 2018-12-27 | Cisplatin | 02 | null | 230013848 | ENZALUTAMIDE |
| 230001352 | 230000957 | 1.7 | 58 | Adjuvant (A) | 2016-02-05 | 2017-03-03 | Trastuzumab Subcutaneous | N | N | 230013848 | CARBOPLATIN |
| 230001353 | 230000957 | 1.88 | 101.6 | Neo-adjuvant (N) | 2017-06-03 | 2017-06-04 | Capecitabine + Oxaliplatin 21day | N | N | 230013848 | NOT MATCHED |
| 230001354 | 230000958 | 1.62 | 55 | Palliative (P) | 2015-11-20 | 2015-11-28 | Docetaxel + Nintedanib | N | N | 230014179 | CYTARABINE |
| 230001355 | 230000960 | 1.73 | 67.75 | Adjuvant (A) | 2013-07-11 | 2013-07-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | 99 | N | 230014255 | BENDAMUSTINE + RITUXIMAB |
| 230001356 | 230000961 | 1.58 | 61.7 | Not known (9) | null | 2017-06-18 | Sorafenib | null | N | 230014292 | OXALIPLATIN + MDG |
| 230001357 | 230000962 | null | 71 | Palliative (P) | 2017-03-02 | 2017-03-12 | TRASTUZUMAB | N | null | 230014410 | TRASTUZUMAB |
| 230001358 | 230000964 | 1.59 | null | Adjuvant (A) | 2016-04-13 | 2016-06-26 | Trastuzumab 21 day maintenance | N | N | 230014444 | OXALIPLATIN + MDG |
| 230001359 | 230000965 | 1.84 | 85.2 | Neo-adjuvant (N) | 2014-02-09 | 2014-02-10 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 230014472 | CVP R |
| 230001360 | 230000966 | 1.81 | 65.3 | Curative (C) | null | 2018-11-08 | Paclitaxel 80mg/m2 day 1 8 15 | 99 | N | 230014472 | CAPECITABINE |
| 230001361 | 230000967 | 1.63 | 61.1 | Disease modification (D) | 2017-01-19 | 2017-01-19 | Docetaxel + Trastuzumab (Maint) | 02 | null | 230014731 | TRASTUZUMAB |
| 230001362 | 230000968 | null | null | Palliative (P) | 2017-01-16 | 2017-01-17 | FLUOROURACIL + OXALIPLATIN | 02 | N | 230015009 | ABIRATERONE |
| 230001363 | 230000970 | 1.7 | null | Curative (C) | 2017-03-13 | 2017-04-30 | FEC | N | null | 230015009 | CVP R |
| 230001364 | 230000971 | 1.81 | 87 | Palliative (P) | 2018-01-14 | 2018-02-15 | Oxaliplatin + Modified de Gramont | 02 | N | 230015104 | IRINOTECAN + MDG |
| 230001365 | 230000971 | 1.63 | 73.3 | Palliative (P) | 2013-09-19 | 2013-10-06 | Methotrexate intrathecal | N | N | 230015104 | LENVATINIB |
| 230001366 | 230001414 | 1.82 | 92.9 | Adjuvant (A) | 2015-04-22 | 2015-05-26 | Oxaliplatin + Modified de Gramont | N | N | 230015783 | CHOP R |
| 230001367 | 230000972 | null | 70.5 | Palliative (P) | 2015-10-04 | 2015-10-05 | Trastuzumab 21 day maintenance | 02 | N | 230015793 | FEC |
| 230001368 | 230000973 | 1.66 | null | Palliative (P) | 2015-12-28 | 2016-01-04 | AFLIBERCEPT + FU + IRINOTECAN | N | N | 230016390 | PIXANTRONE |
| 230001369 | 230000974 | 1.75 | 107 | Palliative (P) | 2014-10-16 | 2014-10-31 | VANDETANIB | 02 | N | 230016462 | SORAFENIB |
| 230001370 | 230000977 | 1.7 | 63.6 | Adjuvant (A) | 2014-08-12 | 2014-08-26 | Methotrexate High Dose (3g/m2) | 02 | N | 230016906 | CRIZOTINIB |